Augmented efficacy of exogenous extracellular vesicles targeted to injured kidneys
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Ferguson, Christopher M.
Lerman, Lilach O.
Text and Data Mining valid from 2020-09-14
Version of Record valid from 2020-09-14
28 January 2020
3 August 2020
20 August 2020
14 September 2020
L.O.L. receives funding from Novo Nordisk and advises Weijian Technologies and AstraZeneca.